Search

Your search keyword '"Ikonen N"' showing total 116 results
Start Over Author "Ikonen N"
116 results on '"Ikonen N"'

4. Genomic and epidemiological report of the recombinant XJ lineage SARS-CoV-2 variant, detected in northern Finland, January 2022

Author

Lindh, E. (Erika), Smura, T. (Teemu), Blomqvist, S. (Soile), Liitsola, K. (Kirsi), Vauhkonen, H. (Hanna), Savolainen, L. (Laura), Ikonen, J. (Jaana), Ronkainen, J. (Jukka), Taskila, J. (Jyri), Sakaranaho, P. (Pertti), Savolainen-Kopra, C. (Carita), Vapalahti, O. (Olli), Ikonen, N. (Niina), Lindh, E. (Erika), Smura, T. (Teemu), Blomqvist, S. (Soile), Liitsola, K. (Kirsi), Vauhkonen, H. (Hanna), Savolainen, L. (Laura), Ikonen, J. (Jaana), Ronkainen, J. (Jukka), Taskila, J. (Jyri), Sakaranaho, P. (Pertti), Savolainen-Kopra, C. (Carita), Vapalahti, O. (Olli), and Ikonen, N. (Niina)

Abstract

Recombinant sequences of the SARS-CoV-2 Omicron variant were detected in surveillance samples collected in north-western Finland in January 2022. We detected 191 samples with an identical genome arrangement in weeks 3 to 11, indicating sustained community transmission. The recombinant lineage has a 5’-end of BA.1, a recombination breakpoint between orf1a and orf1b (nucleotide position 13,296–15,240) and a 3’-end of BA.2 including the S gene. We describe the available genomic and epidemiological data about this currently circulating recombinant XJ lineage.

Published
2022

5. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

Author

Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A. K., Abdelrahman T., Riccardo F., Stefanelli P., Di Martino A., Bella A., Lo Presti A., Casaca P., Moreno J., Borges V., Isidro J., Ferreira R., Gomes J. P., Dotsenko L., Suija H., Epstein J., Sadikova O., Sepp H., Ikonen N., Savolainen-Kopra C., Blomqvist S., Mottonen T., Helve O., Gomes-Dias J., Adlhoch C., Macori G., Russell L., Yandle Z., Bennett C., O'Byrne E., Murphy A., Tuite G., Conroy A., Duffy M., Morley U., Keoghan B., Ford I., Kennedy M., McDonnell S., Flynn A., Clarke A., Crowley A., Martin C., Kelly E., Foxton J., Hare D., Dunford L., Connell J., Moran J., Dean J., Fanning S., Rajan L., De Gascun C., Kenny J., Cotter P., Walsh C., Lawton E., Fitzpatrick A., Mullins E., Della Bartola M., McCabe M., Stapleton P., Meaney C., Fanning L., Prentice M., MacSharry J., Dempsey C., Mallon P., Leon A., Chaturvedi A., Coughlan S., McAndrew G., Reddington K., Walsh F., Fitzpatrick D., Smyth C., O'Dwyer T., Chambers T., Clarke L., Jebb D., Klopp J., Kavanagh D., Haslam K., Buckley P., Lemass K., Fitzpatrick F., Burns K., Cafferkey J., Richmond A., Foley M., Sanchez-Morgado J., Chalapati S., Pinnamaneni N., Crosbie C., Limbachiya D., Tinago W., Garcia Leon A. A., Miles S., Alalwan D., Negi R., Macken A., Feeney E., Kenny G., McCann K., Kelly N., Blair M., McCann R., Kenny C., O'Brion C., Waqas S., Savinelli S., Doran P., Bracken T., Varghese P., Lambert J. S., Cotter A., Muldoon E., Sheehan G., McGinty T., Lambert J., Green S., Leamy K., de Barra E., McConkey S., Kelly C., Horgan M., Sadlier C., Yousif O., O'Donnell J., Fitzgerald M., Petty-Saphon N., Cuddihy J., Fiore S., Fabiani C., Benedetti E., Di Mario G., Facchini M., Puzelli S., Calzoletti L., Fontana S., Venturi G., Fortuna C., Marsili G., Amendola A., Stuppia L., Savini G., Picerno A., Lopizzo T., Dell'Edera D., Minchella P., Greco F., Mauro M. V., Viglietto G., Atripaldi L., Limone A., D'Agaro P., Licastro D., Marcello A., Capobianchi M. R., Icardi G., Bruzzone B., Lillo F., Orsi A., Pariani E., Baldanti F., Gismondo M. R., Maggi F., Caruso A., Ceriotti F., Boniotti B., Bagnarelli P., Garofalo S., Scutella M., Pagani E., Collini L., Ghisetti V., Ru G., Chironna M., Parisi A., Rubino S., Serra C., Piras G., Coghe F., Vitale F., Tramuto F., Scalia G., Palermo C. I., Mancuso G., Di Gaudio F., Vullo S., Reale S., Cusi M. G., Rossolini G. M., Pistello M., Mencacci A., Camilloni B., Severini S., Di Benedetto M., Calogero T., Monne I., Biscaro V., COVID Study Groups, Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A.K., Abdelrahman T., Riccardo F., Stefanelli P., Di Martino A., Bella A., Lo Presti A., Casaca P., Moreno J., Borges V., Isidro J., Ferreira R., Gomes J.P., Dotsenko L., Suija H., Epstein J., Sadikova O., Sepp H., Ikonen N., Savolainen-Kopra C., Blomqvist S., Mottonen T., Helve O., Gomes-Dias J., Adlhoch C., Macori G., Russell L., Yandle Z., Bennett C., O'Byrne E., Murphy A., Tuite G., Conroy A., Duffy M., Morley U., Keoghan B., Ford I., Kennedy M., McDonnell S., Flynn A., Clarke A., Crowley A., Martin C., Kelly E., Foxton J., Hare D., Dunford L., Connell J., Moran J., Dean J., Fanning S., Rajan L., De Gascun C., Kenny J., Cotter P., Walsh C., Lawton E., Fitzpatrick A., Mullins E., Della Bartola M., McCabe M., Stapleton P., Meaney C., Fanning L., Prentice M., MacSharry J., Dempsey C., Mallon P., Leon A., Chaturvedi A., Coughlan S., McAndrew G., Reddington K., Walsh F., Fitzpatrick D., Smyth C., O'Dwyer T., Chambers T., Clarke L., Jebb D., Klopp J., Kavanagh D., Haslam K., Buckley P., Lemass K., Fitzpatrick F., Burns K., Cafferkey J., Richmond A., Foley M., Sanchez-Morgado J., Chalapati S., Pinnamaneni N., Crosbie C., Limbachiya D., Tinago W., Garcia Leon A.A., Miles S., Alalwan D., Negi R., Macken A., Feeney E., Kenny G., McCann K., Kelly N., Blair M., McCann R., Kenny C., O'Brion C., Waqas S., Savinelli S., Doran P., Bracken T., Varghese P., Lambert J.S., Cotter A., Muldoon E., Sheehan G., McGinty T., Lambert J., Green S., Leamy K., de Barra E., McConkey S., Kelly C., Horgan M., Sadlier C., Yousif O., O'Donnell J., Fitzgerald M., Petty-Saphon N., Cuddihy J., Fiore S., Fabiani C., Benedetti E., Di Mario G., Facchini M., Puzelli S., Calzoletti L., Fontana S., Venturi G., Fortuna C., Marsili G., Amendola A., Stuppia L., Savini G., Picerno A., Lopizzo T., Dell'Edera D., Minchella P., Greco F., Mauro M.V., Viglietto G., Atripaldi L., Limone A., D'Agaro P., Licastro D., Marcello A., Capobianchi M.R., Icardi G., Bruzzone B., Lillo F., Orsi A., Pariani E., Baldanti F., Gismondo M.R., Maggi F., Caruso A., Ceriotti F., Boniotti B., Bagnarelli P., Garofalo S., Scutella M., Pagani E., Collini L., Ghisetti V., Ru G., Chironna M., Parisi A., Rubino S., Serra C., Piras G., Coghe F., Vitale F., Tramuto F., Scalia G., Palermo C.I., Mancuso G., Di Gaudio F., Vullo S., Reale S., Cusi M.G., Rossolini G.M., Pistello M., Mencacci A., Camilloni B., Severini S., Di Benedetto M., Calogero T., Monne I., Biscaro V., and COVID Study Groups

Subjects
Infecções Respiratórias, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Critical Care, Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), variants of concern, Settore MED/42 - Igiene Generale E Applicata, 03 medical and health sciences, 0302 clinical medicine, Virology, Internal medicine, Medicine, Humans, Intensive care admission, 030212 general & internal medicine, COVID-19, Europe, SARS-CoV-2, surveillance, Surveillance, business.industry, 030503 health policy & services, Public Health, Environmental and Occupational Health, Odds ratio, Confidence interval, Variants of Concern, COVID-19, Europe, SARS-CoV-2, surveillance, variants of concern, 0305 other medical science, business, Rapid Communication, Human
Abstract

COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs. We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8). ECDC internal funds. The ICSC and the AIID Cohort are supported by Science Foundation Ireland under the Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding Call (Grant number: COVID-RRC 20/COV/0103 and COVID-RRC 20/COV/0305). info:eu-repo/semantics/publishedVersion

Published
2021

7. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.

Author

Funk, T, Pharris, A, Spiteri, G, Bundle, N, Melidou, A, Carr, M, Gonzalez, G, Garcia-Leon, A, Crispie, F, O'Connor, L, Murphy, N, Mossong, J, Vergison, A, Wienecke-Baldacchino, AK, Abdelrahman, T, Riccardo, F, Stefanelli, P, Di Martino, A, Bella, A, Lo Presti, A, Casaca, P, Moreno, J, Borges, V, Isidro, J, Ferreira, R, Gomes, JP, Dotsenko, L, Suija, H, Epstein, J, Sadikova, O, Sepp, H, Ikonen, N, Savolainen-Kopra, C, Blomqvist, S, Möttönen, T, Helve, O, Gomes-Dias, J, Adlhoch, C, COVID study groups, Funk, T, Pharris, A, Spiteri, G, Bundle, N, Melidou, A, Carr, M, Gonzalez, G, Garcia-Leon, A, Crispie, F, O'Connor, L, Murphy, N, Mossong, J, Vergison, A, Wienecke-Baldacchino, AK, Abdelrahman, T, Riccardo, F, Stefanelli, P, Di Martino, A, Bella, A, Lo Presti, A, Casaca, P, Moreno, J, Borges, V, Isidro, J, Ferreira, R, Gomes, JP, Dotsenko, L, Suija, H, Epstein, J, Sadikova, O, Sepp, H, Ikonen, N, Savolainen-Kopra, C, Blomqvist, S, Möttönen, T, Helve, O, Gomes-Dias, J, Adlhoch, C, and COVID study groups

Abstract

We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8).

Published
2021

9. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

Author

Rondy, M., Gherasim, A., Casado, I., Launay, O., Rizzo, C., Pitigoi, D., Mickiene, A., Marbus, S. D., Machado, A., Syrjanen, R. K., Pem-Novose, I., Horvath, J. K., Larrauri, A., Castilla, J., Vanhems, P., Alfonsi, V., Ivanciuc, A. E., Kuliese, M., Van Gageldonk-Lafeber, R., Gomez, V., Ikonen, N., Lovric, Z., Ferenczi, A., Moren, A., Pozo, F., Garcia, M., Latorre, M., Omenaca, M., Oribe Amores, M., Munoz, N., Cilla, G., Fernandino, L., Martinez-Baz, I., Navascues, A., Perez-Garcia, A., Aguinaga, A., Ezpeleta, C., Bella, A., Appelgren, E. C., Castrucci, M. R., Puzelli, S., Chironna, M., Germinario, C., Ansaldi, F., Manini, I., Montomoli, E., Lupulescu, E., Lazar, M., Mihai, M. E., Cherciu, C. M., Dinu, S., Tecu, C., Nitescu, M., Bacruban, R., Azamfire, D., Dumitrescu, A., Ianosik, E., Ceausu, E., Popescu, C. P., Florescu, S. A., Tardei, G., Bejan, C., Teodor, A., Juganariu, G., Plesca, C., Duca, E., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Agostini, C., Ray, M., Merle, C., Foulongne, V., Lina, B., Laine, F., De Guibert, S., Lagathu, G., Tattevin, P., Jouneau, S., Esvant, A., Le Gallou, T., Carrat, F., Mawuvi, G., Chau, F., Nohynek, H., Haveri, A., Gefenaite, G., Velyvyte, D., Jancoriene, L., Zablockiene, B., Ambrozaitis, A., Grimalauskaite, R., Damuleviciene, G., Lesauskaite, V., Bagdonas, A., Nunes, B., Kislaya, I., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Bernard, K., Kurecic-Filipovic, S., Visekruna Vucina, V., Topic, A., Papic, N., Budimir, J., Oroszi, B., Meijer, A., Van Der Hoek, W., Schneeberger, P. M., EpiConcept [Paris], Institute of Health 'Carlos III', CIBER de Epidemiología y Salud Pública (CIBERESP), IDISNA, Pamplona, CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Istituto Superiore di Sanità (ISS), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Lithuanian University of health Sciences, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Health and Welfare [Helsinki], Croatian Institute of Public Health [Zagreb] (CIPH), Office of the Chief Medical Officer, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Laboratoire des pathogènes émergents -- Emerging Pathogens Laboratory (LPE-Fondation Mérieux), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institute of Biology Bucharest of Romanian Academy, Epidemiology Department, Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Istituto Superiore di Sanità Rome, Rome, Italy, Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), EpiConcept, Unión Europea, CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), F-CRIN, I-REIVAC, Institut National de la Santé et de la Recherche Médicale ( INSERM ), National Center for Epidemiology Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], 'Carol Davila' University of Medicine and Pharmacy, National Institute for Public Health and the Environment [Bilthoven] ( RIVM ), Instituto Nacional de Saúde Doutor Ricardo Jorge, Croatian Institute of Public Health, Zagreb, Hospices Civils de Lyon ( HCL ), Centre International de Recherche en Infectiologie ( CIRI ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-École normale supérieure - Lyon ( ENS Lyon ), Istituto Superiore de Sanita, HAL-UPMC, Gestionnaire, École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, 0301 basic medicine, Pediatrics, Epidemiology, Efetividade da Vacina Antigripal, A(H3N2), Influenza, cases control, elderly, hospitalisation, vaccine effectiveness, Elderly, 0302 clinical medicine, vaccine, Outcome Assessment, Health Care, Influenza A Virus, Hospitalisation, awareness, 030212 general & internal medicine, media_common, Vaccine effectiveness, virus diseases, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Middle Aged, Hospitals, 3. Good health, Hospitalization, Influenza Vaccines, H3N2 Subtype, Female, Seasons, influenza, Rapid Communication, Human, Adult, medicine.medical_specialty, Adolescent, Influenza vaccine, 030106 microbiology, Outcome Assessment (Health Care), 03 medical and health sciences, [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology, Virology, Influenza, Human, medicine, Aged, European Union, Humans, Influenza A Virus, H3N2 Subtype, media_common.cataloged_instance, Vacina Antigripal, European union, Cases control, Cases Control, business.industry, Public health, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Case-control study, Influenza a, Confidence interval, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Emergency medicine, [ SDV.IMM.VAC ] Life Sciences [q-bio]/Immunology/Vaccinology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Prevention control, business
Abstract

Members of the I-Move+hospital working group - Portugal: B. Nunes, I. Kislaya, A.P. Rodrigues (National Health Institute Doutor Ricardo Jorge, Lisbon), V. Gomes, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal). In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate. Funding: The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). info:eu-repo/semantics/publishedVersion

Published
2017

10. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza

Author

Rondy, M., Launay, O., Castilla, J., Costanzo, S., Puig-Barbera, J., Gefenaite, G., Larrauri, A., Rizzo, C., Pitigoi, D., Syrjanen, R. K., Machado, A., Filipovic, S. K., Horvath, J. K., Paradowska-Stankiewicz, I., Marbus, S., Moren, A., Valenciano, M., Lenzi, N., Lesieur, Z., Loulergue, P., Galtier, F., Ray, M., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Casado, I., Diaz-Gonzalez, J., Guevara, M., Martinez-Baz, I., Fernandino, L., Navascues, A., Ezpeleta, C., Chamorro, J., Barrado, L., Ortega, M. T., De Gaetano Donati, K., Cauda, R., Donato, C., Taccari, F., Campana, L., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., Alfonsi, V., Bella, A., Puzelli, S., Castrucci, M. R., Orsi, A., Ansaldi, F., Manini, I., Montomoli, E., Chironna, M., Germinario, C., Diez-Domingo, J., Sanudo, B., Carratala Munuera, C., Correcher Medina, P., Gil Guillen, V., Larrea Gonzalez, R., Limon Ramirez, R., Mico Esparza, J. L., Mollar Maseres, J., Otero Reigada, M. C., Tortajada Girbes, M., Schwarz Chavarri, G., Ambrozaitis, A., Jancoriene, L., Zablockiene, B., Zagminas, K., Aukse, M., Damuleviciene, G., Grimalauskaite, R., Kuliese, M., Lesauskaite, V., Velyvyte, D., Niesters, H., Stolk, R. P., Zagmines, K., Rahamat-Langendoen, J., Gherasim, A., Pozo, F., Altzibar, J., Arraras, J. G., Cilla, G., Marco, E., Vidal Garcia, M., Omenaca, M., Ivanciuc, A. E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Nohynek, H., Ikonen, N., Haveri, A., Gomez, V., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Visekruna Vucina, V., Kaic, B., Novosel, I. P., Petrovic, G., Ferenczi, A., Oroszi, B., Korczynska, M. R., Brydak, L. B., Cieslik-Tarkota, R., Rozwadowska, B., Skolimowska, G., Hulboj, D., Jakubik, A., Meijer, A., Van Gageldonk-Lafeber, A. B., Research Council of Lithuania, and European Union

Subjects
0301 basic medicine, Male, Veterinary medicine, Immunology and Microbiology (all), medicine.disease_cause, Polymerase Chain Reaction, Aged, Aged, 80 and over, Case-Control Studies, Clinical Laboratory Techniques, Europe, Female, Hospitalization, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Influenza Vaccines, Influenza, Human, Respiratory Tract Infections, Seasons, Sentinel Surveillance, Vaccination, Molecular Medicine, Veterinary (all), Public Health, Environmental and Occupational Health, Infectious Diseases, Seasonal influenza, IMOVE+, 0302 clinical medicine, 80 and over, Influenza A Virus, Influenza A virus, 030212 general & internal medicine, Respiratory tract infections, virus diseases, 3. Good health, H3N2 Subtype, Public Health, Human, medicine.medical_specialty, Influenza vaccine, 030106 microbiology, Virus, Hospital, 03 medical and health sciences, Repeated Vaccination, Internal medicine, medicine, H1N1 Subtype, Influenza Vaccine Effectiveness, General Veterinary, General Immunology and Microbiology, business.industry, Environmental and Occupational Health, Cuidados de Saúde, Case-control study, Influenza, Negative case, influenza vaccination, test negative case control, vaccine effectiveness, business
Abstract

In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). The IMOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. GlaxoSmithKline, Sanofi Pasteur and Sanofi Pasteur MSD financially supported the InNHOVE network. They had no role in study design, data collection, pooled analysis, and publication. We are grateful to all patients, medical staff, study nurses and epidemiologists from the twelve study sites who actively participated in the study. info:eu-repo/semantics/publishedVersion

Published
2017

11. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project

Author

Rondy, Marc, Larrauri, A., Casado, I., Alfonsi, V., Pitigoi, D., Launay, O., Syrjänen, R. K., Gefenaite, G., Machado, A., Vučina, V. V., Horváth, J. K., Paradowska-Stankiewicz, I., Marbus, S. D., Gherasim, A., Díaz-González, J. A., Rizzo, C., Ivanciuc, A. E., Galtier, F., Ikonen, N., Mickiene, A., Gomez, V., Kurečić Filipović, S., Ferenczi, A., Korcinska, M. R., Van Gageldonk-Lafeber, R., Valenciano, M., Altzibar, Jone M., Arraras, Ion Garcia, Cilla, Gustavo, Marco, Elisa, Vidal, Matxalen, Omenaca, Manuel, Castilla, J., Navascues, A., Ezpeleta, C., Barrado, L., Ortega, M. T., Bella, A., Castrucci, M. R., Puzelli, S., Chironna, M., Germinario, C., Ansaldi, F., Orsi, A., Manini, I., Montomoli, E., Lupulescu, E., Lazar, M., Cherciu, C. M., Tecu, C., Mihai, M. E., Nitescu, M., Leca, D., Ceausu, E., Lenzi, N., Lesieur, Z., Loulergue, P., Foulongne, V., Letois, F., Merle, C., Vanhems, P., Lina, B., Nohynek, H., Haveri, A., Kuliese, M., Velyvyte, D., Grimalauskaite, R., Damuleviciene, G., Lesauskaite, V., Jancoriene, L., Zablockiene, B., Ambrozaitis, A., Nunes, B., Rodrigues, A. P., Gomes, V., Corte-Real, R., Pocas, J., Peres, M. J., Kaić, B., Oroszi, B., Brydak, L. B., Cieślak, K., Kowalczyk, D., Szymański, K., Jakubik, A., Skolimowska, G., Hulboj, D., Meijer, A., Van Der Hoek, W., Schneeberger, P. M., Palmieri, Annapina, Giannitelli, Stefania, Ranghiasci, Alessia, Bacruban, Rodica, Azamfire, Delia, Dumitrescu, Aura, Ianosik, Elena, Duca, Elena, Bejan, Codrina, Teodor, Andra, Florescu, Simin-Aysel, Popescu, Corneliu, Tardei, Gratiela, Charpentier, Julien, Marin, Nathalie, Doumenc, Benoit, Le Jeunne, Claire, Krivine, Anne, Momcilovic, Sonia, Benet, Thomas, Amour, Selilah, Henaff, Laetitia, Jokinen, Jukka, Lyytikainen, Outi, Palmu, Arto, Siren, Paivi, Ruokokoski, Esa, Nunes, Baltazar, Rodrigues, Ana Paula, Guiomar, Raquel, Gomes, Victor, Quaresma, Filipa, Vale, Luis, Garcia, Teresa, Bernardo, Teresa, Dias, Liliana, Fonseca, Paula, Amorim, Helena, Rolo, Joao, Pacheco, Helena, Branquinho, Paula, Corte-Real, Rita, Pocas, Jose, Lopes, Paula, Peres, Maria Joao, Ribeiro, Rosa, Duarte, Paula, Pedroso, Ermelinda, Rodrigues, Sara, Silverio, Ana Rita, Pedreira, Diana Gomes, Fonseca, Marta Ferreira, Vince, Adriana, Topić, Antea, Papić, Neven, Mihalić, Jelena Budimir, Novosel, Iva Pem, Petrović, Goranka, Zajec, Martina, Draženović, Vladimir, Hercegh, Eva, Szalai, Balint, Antmann, Katalin, Nagy, Kamilla, Unión Europea, EpiConcept, Institute of Health Carlos III, CIBER de Epidemiología y Salud Pública (CIBERESP), Istituto Superiore de Sanita, University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute for Health and Welfare [Helsinki], and National Institute for Public Health and the Environment [Bilthoven] (RIVM)

Subjects
Infecções Respiratórias, 0301 basic medicine, Male, Heart disease, Epidemiology, Efetividade da Vacina Antigripal, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Outcome Assessment, Health Care, 80 and over, Influenza A Virus, Medicine, 030212 general & internal medicine, Aged, 80 and over, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Vaccination, virus diseases, 3. Good health, Europe, Hospitalization, Influenza Vaccines, case control, elderly, hospitalisation, influenza, severe acute respiratory infection, vaccine effectiveness, vaccine-preventable diseases, Vaccine-preventable diseases, Female, Public Health, Seasons, Research Article, Human, medicine.medical_specialty, Influenza vaccine, 030106 microbiology, Aged, Humans, Influenza B virus, Influenza, Human, Logistic Models, Outcome Assessment (Health Care), Sentinel Surveillance, Vaccine Potency, Public Health, Environmental and Occupational Health, Virology, Hospital, 03 medical and health sciences, Diabetes mellitus, Internal medicine, H1N1 Subtype, Vacina Antigripal, Intensive care medicine, business.industry, Environmental and Occupational Health, Cuidados de Saúde, Case-control study, medicine.disease, Influenza, Confidence interval, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, business
Abstract

Members of the I-MOVE+ project - Portugal: Baltazar Nunes, Ana Paula Rodrigues, Raquel Guiomar (Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal), Victor Gomes, Filipa Quaresma, Luis Vale, Teresa Garcia, Teresa Bernardo, Liliana Dias, Paula Fonseca, Helena Amorim, João Rolo, Helena Pacheco, Paula Branquinho, Rita Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon, Portugal),José Poças, Paula Lopes, Maria João Peres, Rosa Ribeiro, Paula Duarte, Ermelinda Pedroso, Sara Rodrigues, Ana Rita Silvério, Diana Gomes Pedreira, Marta Ferreira Fonseca, (Centro Hospitalar de Setúbal, Setúbal, Portugal). We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases. The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. info:eu-repo/semantics/publishedVersion

Published
2017

13. The potential risks and impact of the start of the 2015-2016 influenza season in the WHO European Region: a rapid risk assessment

Author

Tjon‐Kon‐Fat, Raïssa, Meerhoff, Tamara, Nikisins, Sergejs, Pires, João, Pereyaslov, Dmitriy, Gross, Diane, Brown, Caroline, Drishti, A., Hasibra, I., Kota, M., Simaku, A., Sarkisian, S., Torosyan, L., El Belazi, G., Hain, C., Lachner, P., Muchl, R., Popow‐Kraupp, T., Redlberger‐Fritz, M., Strauss, R., Abdullayeva, N., Salimov, O., Gribkova, N., Shimanovich, V., Bossuyt, N., Hombrouck, A., Moreels, S., Thomas, I., an Casteren, ., Bastinac, D., Dedejic Ljubovic, A., Kojic, D., Kovacevic Suljkanovic, M., Kuzmanovic, M., Vukmir Rodic, N., Georgieva, T., Kojouharova, M., Korsun, N., Drazenovic, V., Erceg, M., Kurecic‐Filipovic, S., Simunovic, A., Visekruna, V.V., Bagatzouni, D., Elia, A., Koliou, M., Havlickova, M., Jirincova, H., Kyncl, J., Bragstad, K., Kolsen Fischer, T., Krause, K.L., Mazick, A., Trebbien, R., Dontsenko, I., Dotsenko, L., Pokras, L., Sadikova, O., Ikonen, N., Lyytikainen, O., Murtopuro, S., Ruutu, P., Behillil, S., Belchior, E., Blanchon, T., Bonmarin, I., Bruno, L., Cohen, J.M., Enouf, V., Levy, B.D., Mosnier, A., Turbelin, C., Valette, M., an der Werf, ., Chakhunashvili, G., Machablishvili, A., Zakhashvili, K., Andreas, G., Buda, S., Eckmanns, T., Krause, G., Poggensee, G., Schweiger, B., Kossivakis, A., Malisiovas, N., Mentis, A., Spala, G., Csohan, A., Jankovics, I., Kaszas, K., Molnar, Z., Rozsa, M., Gudnason, T., Löve, A., Sigmundsdottir, G., Coughlan, S., Domegan, L., Duffy, M., Igoe, D., O'Donnell, J., O'Flanagan, D., Waters, A., Kaufman, Z., Mandelboim, M., Bella, A., Donatelli, I., Pompa, M.G., Rizzo, C., Amandosova, D., Kuatbaeva, A., Nusupbaeva, G., Smagulova, M., Smagul, M., Sultanova, M., Otorbaeva, D., Saparova, G., Butirina, R., Nikiforova, R., Storozenko, J., Zamjatina, N., Griskevicius, A., Lipnickiene, V., Muralyte, S., Mossong, J., Opp, M., Barbara, C., Graziella, Z., Maistre, M.J., Melillo, T., Rakocevic, B., Vratnica, Z., Hooiveld, I., de Lange, M., Dijkstra, F., Donker, G., Meijer, A., Rimmelzwaan, G., Teirlinck, A., van der Hoek, W., Dudman, S., Hauge, S.H., Hungnes, O., Kilander, A., Tonnessen, R., Bednarska, K., Brydak, L., Wozniak‐Kosek, A., Zielinski, A., Guiomar, R., Nunes, B., Eder, V., Spinu, C., Alexandrescu, V., Lupulescu, E., Popovici, F., Burtseva, E., Komissarov, A., Smorodintseva, E., Sominina, A., Dimitrijevic, D., Filipovic, S., Staronova, E., Berginc, N., Prosenc, K., Socan, M., Ucakar, V., Grgic Vitek, M., Casas, I., de Lejarazu, R. Ortiz, Larrauri, A., Pozo, F., Vega, T., Ali, M., Brytting, M., Dahl, H., Englund, H., Tegnell, A., Wallensten, A., Wiman, A., Born, R., Cordey, S., Kamolov, M., Bosevska, G., Karadzovski, Z., Kuzmanovska, G., Mikik, V., Korukluoglu, G., Topal, S., Ashyrova, A., Ovliyakulova, G., Demchyshyna, I., Dykhanovska, T., Mironenko, A., Blatchford, O., Carman, W., Coyle, P., Gunson, R., Kearns, C., MacLean, A., Mcmenamin, J., Moore, C., Nugent, C., Pebody, R., Phin, N., Reynolds, A., Smyth, B., Watson, J., Zambon, M., Dzemileva, S., and Rakhimov, R.

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Epidemiology, Influenza season, Influenza A(H1N1)pdm09 virus, influenza A(H1N1)pdm09 virus, Seasonal influenza, 03 medical and health sciences, Environmental protection, Virology, Environmental health, Estado de Saúde, 2015–2016 Influenza season, Public Health, Environmental and Occupational Health, virus diseases, 1103 Clinical Sciences, European region, 030112 virology, Europe, 030104 developmental biology, Infectious Diseases, Geography, 1117 Public Health And Health Services, 2015-2016 Influenza season, Original Article, seasonal influenza, Determinantes da Saúde e da Doença, WHO European Region, Risk assessment
Abstract

WHO European Region Influenza Network: P.Conde, I. Costa, P. Crostovão, R. Guiomar, B. Nunes, P.Pechirra, A. Rodrigues (Portugal) BACKGROUND: Countries in the World Health Organization (WHO) European Region are reporting more severe influenza activity in the 2015-2016 season compared to previous seasons. OBJECTIVES: To conduct a rapid risk assessment to provide interim information on the severity of the current influenza season METHODS: Using the WHO manual for rapid risk assessment of acute public health events and surveillance data available from Flu News Europe, an assessment of the current influenza season from 28 September 2015 (week 40/2015) up to 31 January 2016 (week 04/2016) was made compared with the 4 previous seasons. RESULTS: The current influenza season started around week 51/2015 with higher influenza activity reported in eastern Europe compared to Western Europe. There is a strong predominance of influenza A(H1N1)pdm09 compared to previous seasons, but the virus is antigenically similar to the strain included in the seasonal influenza vaccine. Compared to the 2014/2015 season, there was a rapid increase in the number of severe cases in eastern European countries with the majority of such cases occurring among adults aged

Published
2016

14. Laboratory capability and surveillance testing for middle east respiratory syndrome coronavirus infection in the who European region, June 2013

Author

Pereyaslov, D., Rosin, P., Palm, D., Zeller, H., Gross, D., Brown, C. S., Struelens, M. J., Robo, A., Hatibi, I. H., Alis, J. C., Sargsyan, S., Gurbanov, S., Gribkova, N., Ranst, M., Ieven, G., Patteet, S., Tomic, S., Korsun, N., Drazenovic, V., Pieridou-Bagkatzouni, D., Jirincova, H., Havlickova, M., Fomsgaard, A., Rae, K., Lappalainen, M., Ikonen, N., Lina, B., Sylvie van der WERF, Manuguerra, J. -C, Machablishvili, A., Eickmann, M., Wolff, T., Dobler, G., Schmidt-Chanasit, J., Drosten, C., Papa, A., Mentis, A. F., Kis, Z., Löve, A., Coughlan, S., Mandelboim, M., Capobianchi, M. R., Landini, M. P., Baldanti, F., Palu, G., Ghisetti, V., Donatelli, I., Nusupbayeva, G., Tokhtabakiyeva, Z., Kasymbekova, K., Storozenko, J., Erne, S., Griskevicius, A., Opp, M., Barbara, C., Vratnica, Z., Reusken, C., Dudman, S. G., Hungnes, O., Pancer, K., Guiomar, R., Eder, V., Lupulescu, E., Yatsyshina, S., Pisareva, M., Buzitskaya, Z., Sergeev, A., Nedeljković, J., Staroňová, E., Županc, T. A., Petrovec, M., Korva, M., Prosenc, K., Casas, I., Gaines, H., Cherpillod, P., Zakirova, N., Bosevska, G., Altas, B., Ciblak, M., Mironenko, A., Dykhanovska, T., Demchyshyna, I., Bermingham, A., Rakhimov, R., Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Experts of the MERS-CoV Working Group Members of this working group who provided survey data: Albania: Alma Robo, Iris Hasibra (Hatibi), Institute of Public Health, Tirana Andorra: Josep Casals Alis, Ministry of Health, Welfare and Labour, Andorra la Vella Armenia: Shushan Sargsyan, Virology Laboratory, Centre for Diseases Control and Prevention, Yerevan Austria: Stephan Aberle, Department of Virology, Medical University of Vienna, Vienna Azerbaijan: Sadraddin Gurbanov, National Virology Laboratory, National Anti-Plague Station, Baku Belarus: Natalia Gribkova, Laboratory for Influenza and Influenza-like Diseases, Republican Research and Practical Center for Epidemiology and Microbiology, Minsk Belgium: Marc Van Ranst, Greet Ieven and Sophie Patteet, National Reference Centre of Respiratory Viruses, University Hospital Leuven and UZA Antwerpen, Antwerpen Bosnia and Herzegovina: Stanka Tomic, Microbiology Department, Institute of Public Health of the Republic of Srpska, Banja Luka Bulgaria: Neli Korsun, National Laboratory 'Influenza and ARD', Department of Virology, National Centre of Infectious and Parasitic Diseases, Sofia Croatia: Vladimir Drazenovic, National Influenza Centre, Croatian National Institute of Public Health, Zagreb Cyprus: Despo Pieridou-Bagkatzouni, Microbiology Department, Nicosia General Hospital, Nicosia Czech Republic: Helena Jirincova, Martina Havlickova, National Reference Laboratory for Influenza, National Institute for Public Health, Prague Denmark: Anders Fomsgaard, Virus Research and Development Laboratory, Department Microbiology Diagnostic and Virology, Statens Serum Institut, Copenhagen Estonia: Külli Rae, Laboratory of Communicable Diseases, Health Board, Tallinn Finland: Maija Lappalainen, Department of Virology and Immunology, Helsinki University Hospital, Laboratory Services (HUSLAB) and Niina Ikonen, Virology Unit, National Institute for Health and Welfare, Helsinki France: Bruno Lina, Centre National de Référence des Virus Influenza – HCL, Lyon and Sylvie van der Werf, Unit of Molecular Genetics of RNA viruses, Institut Pasteur and Jean-Claude Manuguerra, Cellule d’Intervention Biologique d’Urgence (CIBU), Institut Pasteur, Paris Georgia: Ann Machablishvili, National Influenza Centre, National Centre for Disease Control and Public Health, Tbilisi Germany: Markus Eickmann, Institut für Virologie der Philipps-Universität in Marburg and Thorsten Wolff, Div of Influenza and other Respiratory viruses, Robert Koch-Institut, and Dr. Gerhard Dobler, Bundeswehr Instittue of Microbiology, and Jonas Schmidt-Chanasit, WHOCC for Arbovirus and Haemorrhagic Fever Reference and Research at Bernhard Nocht Institute for Tropical Medicine, Hamburg, and Christian Drosten, Virology Institute, Bonn Greece: Anna Papa, National Reference Laboratory for Arboviruses and Hemorrhagic Fever viruses, Aristotle University of Thessaloniki, Thessaloniki and Andreas F. Mentis, National Influenza Reference Laboratory of Southern Greece/Hellenic Pasteur Institute, Athens Hungary: Zoltan Kis, Department for Respiratory Viruses / National Biosafety Laboratory, B. Johan National Center for Epidemiology, Budapest Iceland: Arthur Löve, Department of Virology, Landspitali- National University Hospital, Reykjavik Ireland: Suzie Coughlan, National Virus Reference Laboratory/University College Dublin, Dublin Israel: Michal Mandelboim, Central Virology Laboratory, Sheba Medical Center, Tel Hashomer Italy: Maria R. Capobianchi, Laboratory of Virology/National Institute for Infectious Diseases Lazzaro Spallanzani, and Maria Paola Landini, Regional Center for Emerging Infections (CRREM)/ Unit of Clinical Microbiology, St. Orsola General Hospital, Bologna, and Fausto Baldanti, Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, and Giorgio Palu, Microbiology and Virology/Padova University Hospital, and Valeria Ghisetti, Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Torino, and Isabella Donatelli, National Influenza Centre, Instituto Superiore di Sanita, Kazakhstan: Gaukhar Nusupbayeva, Zarina Tokhtabakiyeva, National Reference Laboratory on Control of Viral Infections, Scientifical-Practical Center of Sanitary and Epidemiological Expertise and Monitoring, Almaty Kyrgyzstan: Kaliya Kasymbekova, Centre of Molecular-Genetic and Microbiological Investigations, Department of State Sanitary Epidemiological Surveillance, Bishkek Latvia: Jelena Storozenko, Riga East University Hospital, Latvian Centre of Infectious Diseases, National Microbiology Reference Laboratory, Riga Liechtenstein: Sabine Erne, Office of Public Health, Country Administration of Principality of Liechtenstein Lithuania: Algirdas Griskevicius, National Public Health Surveillance Laboratory, Vilnius Luxembourg: Matthias Opp, Laboratoire National de Santé, Luxembourg Malta: Christopher Barbara, Pathology Department, Mater Dei Hospital, Msida Montenegro: Zoran Vratnica, Centre for Medical Microbiology, Public Health Institute of Montenegro, Podgorica Netherlands: Chantal Reusken, Centre for Infectious Disease Research, Diagnostics and Screening, National Institute for Public Health and the Environment, Bilthoven Norway: Susanne Gjeruldsen Dudman and Olav Hungnes, Department of Virology, Norwegian Institute of Public Health, Oslo Poland: Katarzyna Pancer, National Institute of Public Health- National Institute of Hygiene, Department of Virology, Warsaw Portugal: Raquel Guiomar, National Influenza Reference Laboratory, Infectious Diseases Department, National Institute of Health, Lisboa Republic of Moldova: Veronica Eder, Laboratory of Viral Respiratory Infections, National Center for Public Health, Chisinau Romania: Emilia Lupulescu, Laboratory for Respiratory Viruses/ NIRDMI Cantacuzino, Bucharest Russian Federation: Svetlana Yatsyshina, Reference Centre for Infection Agents, Central Research Institute of Epidemiology (CRIE), Rospotrebnadzor, Moscow, and Maria Pisareva and Zhanna Buzitskaya, Laboratory of Molecular Virology and Genetic Engineering, Research Institute of Influenza, St Petersburg, and Alexander Sergeev, State Research Center of Virology and Biotechnology VECTOR, Novosibirsk Serbia: Jasminka Nedeljković, Respiratory Department, Torlak Institute of Immunology and Virology, Belgrade Slovakia: Edita Staroňová, National Influenza Center/Public Health Authority, Bratislava Slovenia: Tatjana Avšič Županc, Miroslav Petrovec, Miša Korva, University of Ljubljana, Faculty of Medicine, Institute of Microbiology and Immunology, and Katarina Prosenc, Laboratory for Virology, National Public Health Institute Slovenia, Ljubljana Spain: Inmaculada Casas, Influenza National Reference Laboratory, National Influenza Center-Madrid, Instituto de Salud Carlos III, Majadahonda, Madrid and Ramon Cisterna Clinical microbiology and infection control, Hospital Basurto Bilbao Spain Sweden: Hans Gaines, Swedish Institute for Communicable Disease Control, Stockholm Switzerland: Pascal Cherpillod, National Reference Centre for Emerging Viral Infections, Laboratory of Virology, Division of Infectious Diseases University of Geneva Hospitals, Geneva Tajikistan: Niginamo Zakirova, Virology Laboratory, State Sanitary-Epidemiological Surveillance, Dushanbe The former Yugoslav Republic of Macedonia: Golubinka Bosevska, Laboratory for Virology and Molecular Diagnostics, Institute of Public Health, Skopje Turkey: Basak Altas, National Influenza Centre, Virology Reference and Research Laboratory, Public Health Institutions of Turkey, Ankara, and Meral Ciblak, National Influenza Reference Laboratory, Faculty of Medicine, University of Istanbul, Istanbul Turkmenistan: Central Reference Laboratory, Sanitary Epidemiologic Service, Ashgabat Ukraine: Alla Mironenko, National Influenza Centre, L.V.Gromashevsky Institute of Epidemiology & Infectious diseases NAMS, and Tetiana Dykhanovska and Iryna Demchyshyna, Centre of influenza and ARVI, Central Sanitary and Epidemiological Station, Kiev United Kingdom: Alison Bermingham, Respiratory Virus Unit, Virus Reference Department, Public Health England, London Uzbekistan: Ravshan Rakhimov, National Influenza Centre, Institute of Virology, Tashkent., and We thank the ECDC National Microbiology Focal Points in EU/EEA countries, focal points from laboratories of the EuroFlu and ENIVD networks for coordinating data collection and for dedicated and rapid responses to the surveys.

Subjects
Epidemiology, Middle East respiratory syndrome coronavirus, [SDV]Life Sciences [q-bio], SARS (Disease), MERS (Disease), medicine.disease_cause, World Health Organization, Communicable Diseases, Emerging, World health, Viral genetics, Coronavirus infections -- Laboratory manuals, Environmental protection, Virology, Environmental health, medicine, media_common.cataloged_instance, Humans, European Union, European union, Coronavirus, media_common, Middle East, business.industry, Reverse Transcriptase Polymerase Chain Reaction, Public Health, Environmental and Occupational Health, Reference Standards, European region, Health Surveys, Diseases -- Causes and theories of causation, Middle East Respiratory Syndrome Coronavirus, RNA, Viral, Disease prevention, business, Coronavirus Infections, Laboratories, Sentinel Surveillance, Sequence Analysis
Abstract

Since September 2012, over 90 cases of respiratory disease caused by a novel coronavirus, now named Middle East respiratory syndrome coronavirus (MERS-CoV), have been reported in the Middle East and Europe. To ascertain the capabilities and testing experience of national reference laboratories across the World Health Organization (WHO) European Region to detect this virus, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe conducted a joint survey in November 2012 and a follow-up survey in June 2013. In 2013, 29 of 52 responding WHO European Region countries and 24 of 31 countries of the European Union/European Economic Area (EU/EEA) had laboratory capabilities to detect and confirm MERS-CoV cases, compared with 22 of 46 and 18 of 30 countries, respectively, in 2012. By June 2013, more than 2,300 patients had been tested in 23 countries in the WHO European Region with nine laboratory-confirmed MERS-CoV cases. These data indicate that the Region has developed significant capability to detect this emerging virus in accordance with WHO and ECDC guidance. However, not all countries had developed capabilities, and the needs to do so should be addressed. This includes enhancing collaborations between countries to ensure diagnostic capabilities for surveillance of MERS-CoV infections across the European Region., peer-reviewed

Published
2014

15. Reduced cross-protection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine

Author

University of Helsinki, Department of Medicine, University of Helsinki, Infektiosairaudet (-2009), University of Helsinki, Infektiosairauksien yksikkö, Haveri, A., Ikonen, N., Julkunen, I., Kantele, A., Anttila, V. J., Ruotsalainen, E., Nohynek, H., Lyytikalnen, O., Savolainen-Kopra, C., University of Helsinki, Department of Medicine, University of Helsinki, Infektiosairaudet (-2009), University of Helsinki, Infektiosairauksien yksikkö, Haveri, A., Ikonen, N., Julkunen, I., Kantele, A., Anttila, V. J., Ruotsalainen, E., Nohynek, H., Lyytikalnen, O., and Savolainen-Kopra, C.

Published
2015

16. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: A meta-analysis of A(H1N1)pdm09 serological studies from 19 countries

Author

Van Kerkhove, M.D. Hirve, S. Koukounari, A. Mounts, A.W. Allwinn, R. Bandaranayake Bella Bone, A. Carrat, F. Chadha, M.S. Chen, M. Chi, C.-Y. Cox Cretikos, M. Crowcroft, N. Cutter, J. Donnelly, C.A. de Lamballerie, X. Dellagi Doukas, G. Dudareva-Vizule, S. Ferguson, N.M. Fry, A.M. Gilbert, G.L. Haas, W. Hardelid, P. Horby, P. Huang, Q.S. Hungnes, O. Ikonen, N. Iwatsuki-Horimoto, K. Julkunen, I. Katz, J. Kawaoka, Y. Lalvani, A. Levy-Bruhl, D. Maltezou, H.C. McVernon, J. Miller, M. Mishra, A.C. Moghadami, M. Pawar, S.D. Reed, C. Riley, S. Rizzo, C. Rosella, L. Ross, T.M. Shu, Y. Skowronski, D.M. Sridhar, S. Steens, A. Tandale, B.V. Theodoridou, M. van Boven, M. Waalen, K. Wang, J.-R. Wu, J.T. Xu, C. Zimmer, S.

Abstract

Background: The global impact of the 2009 influenza A(H1N1) pandemic (H1N1pdm) is not well understood. Objectives: We estimate overall and age-specific prevalence of cross-reactive antibodies to H1N1pdm virus and rates of H1N1pdm infection during the first year of the pandemic using data from published and unpublished H1N1pdm seroepidemiological studies. Methods: Primary aggregate H1N1pdm serologic data from each study were stratified in standardized age groups and evaluated based on when sera were collected in relation to national or subnational peak H1N1pdm activity. Seropositivity was assessed using well-described and standardized hemagglutination inhibition (HI titers ≥32 or ≥40) and microneutralization (MN ≥ 40) laboratory assays. The prevalence of cross-reactive antibodies to the H1N1pdm virus was estimated for studies using sera collected prior to the start of the pandemic (between 2004 and April 2009); H1N1pdm cumulative incidence was estimated for studies in which collected both pre- and post-pandemic sera; and H1N1pdm seropositivity was calculated from studies with post-pandemic sera only (collected between December 2009-June 2010). Results: Data from 27 published/unpublished studies from 19 countries/administrative regions - Australia, Canada, China, Finland, France, Germany, Hong Kong SAR, India, Iran, Italy, Japan, Netherlands, New Zealand, Norway, Reunion Island, Singapore, United Kingdom, United States, and Vietnam - were eligible for inclusion. The overall age-standardized pre-pandemic prevalence of cross-reactive antibodies was 5% (95%CI 3-7%) and varied significantly by age with the highest rates among persons ≥65 years old (14% 95%CI 8-24%). Overall age-standardized H1N1pdm cumulative incidence was 24% (95%CI 20-27%) and varied significantly by age with the highest in children 5-19 (47% 95%CI 39-55%) and 0-4 years old (36% 95%CI 30-43%). Conclusions: Our results offer unique insight into the global impact of the H1N1 pandemic and highlight the need for standardization of seroepidemiological studies and for their inclusion in pre-pandemic preparedness plans. Our results taken together with recent global pandemic respiratory-associated mortality estimates suggest that the case fatality ratio of the pandemic virus was approximately 0·02%. © 2013 John Wiley & Sons Ltd.

Published
2013

19. The first detection of influenza in the Finnish pig population: a retrospective study

Author

Nokireki, T., Laine, T., London, L., Ikonen, N., Huovilainen, A., Nokireki, T., Laine, T., London, L., Ikonen, N., and Huovilainen, A.

Abstract

Background: Swine influenza is an infectious acute respiratory disease of pigs caused by influenza A virus. We investigated the time of entry of swine influenza into the Finnish pig population. We also describe the molecular detection of two types of influenza A (H1N1) viruses in porcine samples submitted in 2009 and 2010. This retrospective study was based on three categories of samples: blood samples collected for disease monitoring from pigs at major slaughterhouses from 2007 to 2009; blood samples from pigs in farms with a special health status taken in 2008 and 2009; and diagnostic blood samples from pigs in farms with clinical signs of respiratory disease in 2008 and 2009. The blood samples were tested for influenza A antibodies with an antibody ELISA. Positive samples were further analyzed for H1N1, H3N2, and H1N2 antibodies with a hemagglutination inhibition test. Diagnostic samples for virus detection were subjected to influenza A M-gene-specific real-time RT-PCR and to pandemic influenza A H1N1-specific real-time RT-PCR. Positive samples were further analyzed with RT-PCRs designed for this purpose, and the PCR products were sequenced and sequences analyzed phylogenetically. Results: In the blood samples from pigs in special health class farms producing replacement animals and in diagnostic blood samples, the first serologically positive samples originated from the period July–August 2008. In samples collected for disease monitoring, < 0.1%, 0% and 16% were positive for antibodies against influenza A H1N1 in the HI test in 2007, 2008, and 2009, respectively. Swine influenza A virus of avian-like H1N1 was first detected in diagnostic samples in February 2009. In 2009 and 2010, the avian-like H1N1 virus was detected on 12 and two farms, respectively. The pandemic H1N1 virus (A(H1N1) pdm09) was detected on one pig farm in 2009 and on two farms in 2010. Conclusions: Based on our study, swine influenza of avian-like H1N1 virus was introduced into the Finnish pig

Published
2013

30. Surveillance of influenza in Finland during the 2009 pandemic, 10 May 2009 to 8 March 2010

Author

Lyytikainen O, Kuusi M, Snellman M, Virtanen M, Eskola J, Ronkko E, Ikonen N, Ilkka Julkunen, Ziegler T, and Ruutu P

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Incidence, Infant, Newborn, Infant, Middle Aged, Hospitalization, Young Adult, Age Distribution, Influenza A Virus, H1N1 Subtype, Risk Factors, Child, Preschool, Population Surveillance, Influenza, Human, Humans, Female, Seasons, Morbidity, Sex Distribution, Child, Pandemics, Finland, Aged

31. Start of the 2014/15 influenza season in Europe: Drifted influenza A(H3N2) viruses circulate as dominant subtype

Author

Broberg, E., Snacken, R., Adlhoch, C., Beauté, J., Galinska, M., Pereyaslov, D., Brown, C., Penttinen, P., Kota, M., Simaku, A., Sarkisian, S., Torosyan, L., Popow-Kraupp, T., Rendi-Wagner, P., Schmid, D., Abdullayeva, N., Salimov, O., Gribkova, N., Shimanovich, V., Thomas, I., Hombrouck, A., Bossuyt, N., Moreels, S., Casteren, V., Ljubovic, A. D., Rodic, N. V., Korsun, N., Kojouharova, M., Georgieva, T., Drazenovic, V., Bagatzouni, D., Koliou, M., Havlickova, M., Jiřincová, H., Kyncl, J., Knudsen, L. K., Mazick, A., Ramona Trebbien, Fischer, T. K., Lilje, L., Pokras, L., Kuznetsova, N., Sadikova, O., Ikonen, N., Lyytikäinen, O., Murtopuro, S., Enouf, V., Lina, B., Valette, M., Werf, S., Bonmarin, I., Sylvie, B., Thierry, B., Turbelin, C., Belchior, E., Machablishvili, A., Zakhashvili, K., Buda, S., Schweiger, B., Kossivakis, A., Georgia, S., Mentis, A., Malisiovas, N., Csohán, Á, Rózsa, M., Jankovics, I., Molnár, Z., Löve, A., Sigmundsdóttir, G., Gudnason, T., Domegan, L., O’flanagan, D., Igoe, D., Waters, A., Duffy, M., Coughlan, S., O Donnell, J., Kaufman, Z., Mandelboim, M., Donatelli, I., Bella, A., Rizzo, C., Pompa, M. G., Puzelli, S., Castrucci, M. R., Katrenova, A., Nusupbaeva, G., Kasymbekova, K., Otorbaeva, D., Nikiforova, R., Zamjatina, N., Erne, S., Griškevicius, A., Lipnickiene, V., Mossong, J., Opp, M., Barbara, C., Melillo, T., Melillo, J. M., Zahra, G., Rakocevic, B., Vratnica, Z., Meijer, A., Teirlinck, A., Dijkstra, F., Donker, G., Rimmelzwaan, G., Lange, M. D., Hungnes, O., Bragstad, K., Hauge, S. H., Tønnessen, R., Dudman, S. G., Bednarska, K., Brydak, L. B., Zielinski, A., Guiomar, R., Pechirra, P., Cristovão, P., Costa, I., Nunes, B., Rodrigues, A., Eder, V., Spinu, C., Alexandrescu, V., Lupulescu, E., Popovici, F., Burtseva, E., Sominina, A., Dimitrijevic, D., Adrovic, S. R., Staronová, E., Mikas, J., Prosenc, K., Berginc, N., Socan, M., Casas, I., Larrauri, A., Pozo, F., Lejarazu, R. O., Pumarola, T., Brytting, M., Englund, H., Wiman, Å, Mahmud, N. N., Born, R., Cordey, S., Tishkova, F., Kamolov, M., Bosevska, G., Kuzmanovska, G., Topal, S., Korukluoglu, G., Ashirova, A., Ovliyakulova, G., Demchyshyna, I., Dykhanovska, T., Mironenko, A., Coyle, P., Maclean, A., Gunson, R., Green, H., Kearns, C., Zambon, M., Nugent, C., Moore, C., Phin, N., Pebody, R., Cottrell, S., Mcmenamin, J., Jessop, L., Dzemileva, S., Rakhimov, R., Mccauley, J., and Daniels, R.

32. Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study.

Author

Simoes MP, Hodcroft EB, Simmonds P, Albert J, Alidjinou EK, Ambert-Balay K, Andrés C, Antón A, Auvray C, Bailly JL, Baldanti F, Bastings C, Beard S, Berengua C, Berginc N, Bloemen M, Blomqvist S, Bosma F, Böttcher S, Bubba L, Buderus S, Cabrerizo M, Calvo C, Celma C, Ceriotti F, Clark G, Costa I, Coste-Burel M, Couderé K, Cremer J, Del Cuerpo Casas M, Daehne T, de Beer J, de Ceano-Vivas M, De Gascun C, de Rougemont A, Dean J, Dembinski JL, Diedrich S, Diez-Domingo J, Dillner L, Dorenberg DH, Ducancelle A, Dudman S, Dyrdak R, Eis-Huebinger AM, Falces-Romero I, Farkas A, Feeney S, Fernandez-Garcia MD, Flipse J, Franck KT, Galli C, Garrigue I, Geeraedts F, Georgieva I, Giardina F, Guiomar R, Hauzenberger E, Heikens E, Henquell C, Hober D, Hönemann M, Howson-Wells H, Hruškar Ž, Ikonen N, Imbert B, Jansz AR, Jeannoël M, Jiřincová H, Josset L, Keeren K, Kramer-Lindhout N, Krokstad S, Lazrek M, Le Guillou-Guillemette H, Lefeuvre C, Lind A, Lunar MM, Maier M, Marque-Juillet S, McClure CP, McKenna J, Meijer A, Menasalvas Ruiz A, Mengual-Chuliá B, Midgley S, Mirand A, Molenkamp R, Montes M, Moreno-Docón A, Morley U, Murk JL, Navascués-Ortega A, Nijhuis R, Nikolaeva-Glomb L, Nordbø SA, Numanovic S, Oggioni M, Oñate Vergara E, Pacaud J, Pacreau ML, Panning M, Pariani E, Pekova L, Pellegrinelli L, Petrovec M, Pietsch C, Pilorge L, Piñeiro L, Piralla A, Poljak M, Prochazka B, Rabella N, Rahamat-Langendoen JC, Rainetova P, Reynders M, Riezebos-Brilman A, Roorda L, Savolainen-Kopra C, Schuffenecker I, Smeets LC, Stoyanova A, Stefic K, Swanink C, Tabain I, Tjhie J, Thouault L, Tumiotto C, Uceda Renteria S, Uršič T, Vallet S, Van Ranst M, Van Wunnik P, Verweij JJ, Vila J, Wintermans B, Wollants E, Wolthers KC, Xavier López-Labrador F, Fischer TK, Harvala H, and Benschop KSM

Subjects
Humans, Europe epidemiology, Child, Preschool, Male, Infant, Female, Child, Adolescent, Myelitis epidemiology, Myelitis virology, Respiratory Tract Infections virology, Respiratory Tract Infections epidemiology, Adult, Central Nervous System Viral Diseases epidemiology, Central Nervous System Viral Diseases virology, Infant, Newborn, Young Adult, Middle Aged, Neuromuscular Diseases epidemiology, Neuromuscular Diseases virology, Aged, Enterovirus Infections epidemiology, Enterovirus Infections virology, Enterovirus D, Human genetics, Enterovirus D, Human classification, Enterovirus D, Human isolation & purification, Phylogeny
Abstract

Enterovirus D68 (EV-D68) infections are associated with severe respiratory disease and acute flaccid myelitis (AFM). The European Non-Polio Enterovirus Network (ENPEN) aimed to investigate the epidemiological and genetic characteristics of EV-D68 infections and its clinical impact during the fall-winter season of 2021-2022. From 19 European countries, 58 institutes reported 10 481 (6.8%) EV-positive samples of which 1004 (9.6%) were identified as EV-D68 (including 852 respiratory samples). Clinical data were reported for 969 cases; 78.9% of infections were reported in children (0-5 years); and 37.9% of cases were hospitalized. Acute respiratory distress was commonly noted (93.1%) followed by fever (49.4%). Neurological problems were observed in 6.4% of cases including 6 diagnosed with AFM. Phylodynamic/Nextstrain and phylogenetic analyses based on 694 sequences showed the emergence of 2 novel B3-derived lineages, with no regional clustering. In conclusion, we describe a large-scale European EV-D68 upsurge with severe clinical impact and the emergence of B3-derived lineages., Competing Interests: Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Published
2024
Full Text
View/download PDF

33. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.

Author

Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, Ruokoranta T, Kuusanmäki H, Ikonen N, Sergeev P, Vähä-Koskela M, Giri AK, Vähärautio A, Kontro M, Porkka K, Pitkänen E, Heckman CA, Wennerberg K, and Aittokallio T

Subjects
Humans, Female, Neoplasms genetics, Neoplasms drug therapy, Neoplasms therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute drug therapy, Machine Learning, Cell Line, Tumor, Ovarian Neoplasms genetics, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Gene Expression Regulation, Neoplastic, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Gene Expression Profiling methods, Drug Resistance, Neoplasm genetics, Single-Cell Analysis methods, Transcriptome, Precision Medicine methods
Abstract

Intratumoral cellular heterogeneity necessitates multi-targeting therapies for improved clinical benefits in advanced malignancies. However, systematic identification of patient-specific treatments that selectively co-inhibit cancerous cell populations poses a combinatorial challenge, since the number of possible drug-dose combinations vastly exceeds what could be tested in patient cells. Here, we describe a machine learning approach, scTherapy, which leverages single-cell transcriptomic profiles to prioritize multi-targeting treatment options for individual patients with hematological cancers or solid tumors. Patient-specific treatments reveal a wide spectrum of co-inhibitors of multiple biological pathways predicted for primary cells from heterogenous cohorts of patients with acute myeloid leukemia and high-grade serous ovarian carcinoma, each with unique resistance patterns and synergy mechanisms. Experimental validations confirm that 96% of the multi-targeting treatments exhibit selective efficacy or synergy, and 83% demonstrate low toxicity to normal cells, highlighting their potential for therapeutic efficacy and safety. In a pan-cancer analysis across five cancer types, 25% of the predicted treatments are shared among the patients of the same tumor type, while 19% of the treatments are patient-specific. Our approach provides a widely-applicable strategy to identify personalized treatment regimens that selectively co-inhibit malignant cells and avoid inhibition of non-cancerous cells, thereby increasing their likelihood for clinical success., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

34. Avian Influenza outbreaks: Human infection risks for beach users - One health concern and environmental surveillance implications.

Author

Tiwari A, Meriläinen P, Lindh E, Kitajima M, Österlund P, Ikonen N, Savolainen-Kopra C, and Pitkänen T

Subjects
Humans, Animals, Environmental Monitoring, Bathing Beaches, One Health, Influenza in Birds epidemiology, Influenza in Birds transmission, Influenza, Human epidemiology, Influenza, Human transmission, Influenza A Virus, H5N1 Subtype, Disease Outbreaks, Birds
Abstract

Despite its popularity for water activities, such as swimming, surfing, fishing, and rafting, inland and coastal bathing areas occasionally experience outbreaks of highly pathogenic avian influenza virus (HPAI), including A(H5N1) clade 2.3.4.4b. Asymptomatic infections and symptomatic outbreaks often impact many aquatic birds, which increase chances of spill-over events to mammals and pose concerns for public health. This review examined the existing literature to assess avian influenza virus (AIV) transmission risks to beachgoers and the general population. A comprehensive understanding of factors governing such crossing of the AIV host range is currently lacking. There is limited knowledge on key factors affecting risk, such as species-specific interactions with host cells (including binding, entry, and replication via viral proteins hemagglutinin, neuraminidase, nucleoprotein, and polymerase basic protein 2), overcoming host restrictions, and innate immune response. AIV efficiently transmits between birds and to some extent between marine scavenger mammals in aquatic environments via consumption of infected birds. However, the current literature lacks evidence of zoonotic AIV transmission via contact with the aquatic environment or consumption of contaminated water. The zoonotic transmission risk of the circulating A(H5N1) clade 2.3.4.4b virus to the general population and beachgoers is currently low. Nevertheless, it is recommended to avoid direct contact with sick or dead birds and to refrain from bathing in locations where mass bird mortalities are reported. Increasing reports of AIVs spilling over to non-human mammals have raised valid concerns about possible virus mutations that lead to crossing the species barrier and subsequent risk of human infections and outbreaks., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

35. Highly pathogenic avian influenza A(H5N1) virus infections on fur farms connected to mass mortalities of black-headed gulls, Finland, July to October 2023.

Author

Kareinen L, Tammiranta N, Kauppinen A, Zecchin B, Pastori A, Monne I, Terregino C, Giussani E, Kaarto R, Karkamo V, Lähteinen T, Lounela H, Kantala T, Laamanen I, Nokireki T, London L, Helve O, Kääriäinen S, Ikonen N, Jalava J, Kalin-Mänttäri L, Katz A, Savolainen-Kopra C, Lindh E, Sironen T, Korhonen EM, Aaltonen K, Galiano M, Fusaro A, and Gadd T

Subjects
Animals, Finland epidemiology, Farms, Orthomyxoviridae Infections veterinary, Orthomyxoviridae Infections virology, Orthomyxoviridae Infections mortality, Orthomyxoviridae Infections epidemiology, Foxes virology, Birds virology, Mink virology, Influenza in Birds virology, Influenza in Birds epidemiology, Phylogeny, Influenza A Virus, H5N1 Subtype genetics, Influenza A Virus, H5N1 Subtype pathogenicity, Influenza A Virus, H5N1 Subtype isolation & purification, Animals, Wild virology, Charadriiformes virology, Disease Outbreaks veterinary
Abstract

Highly pathogenic avian influenza (HPAI) has caused widespread mortality in both wild and domestic birds in Europe 2020-2023. In July 2023, HPAI A(H5N1) was detected on 27 fur farms in Finland. In total, infections in silver and blue foxes, American minks and raccoon dogs were confirmed by RT-PCR. The pathological findings in the animals include widespread inflammatory lesions in the lungs, brain and liver, indicating efficient systemic dissemination of the virus. Phylogenetic analysis of Finnish A(H5N1) strains from fur animals and wild birds has identified three clusters (Finland I-III), and molecular analyses revealed emergence of mutations known to facilitate viral adaptation to mammals in the PB2 and NA proteins. Findings of avian influenza in fur animals were spatially and temporally connected with mass mortalities in wild birds. The mechanisms of virus transmission within and between farms have not been conclusively identified, but several different routes relating to limited biosecurity on the farms are implicated. The outbreak was managed in close collaboration between animal and human health authorities to mitigate and monitor the impact for both animal and human health.

Published
2024
Full Text
View/download PDF

36. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia.

Author

Eldfors S, Saad J, Ikonen N, Malani D, Vähä-Koskela M, Gjertsen BT, Kontro M, Porkka K, and Heckman CA

Subjects
Humans, Nicotinamide Phosphoribosyltransferase, Chromosome Deletion, Chromosomes, Human, Pair 7, Leukemia, Myeloid, Acute genetics, Antineoplastic Agents
Abstract

Abstract: Monosomy 7 and del(7q) (-7/-7q) are frequent chromosomal abnormalities detected in up to 10% of patients with acute myeloid leukemia (AML). Despite unfavorable treatment outcomes, no approved targeted therapies exist for patients with -7/-7q. Therefore, we aimed to identify novel vulnerabilities. Through an analysis of data from ex vivo drug screens of 114 primary AML samples, we discovered that -7/-7q AML cells are highly sensitive to the inhibition of nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is the rate-limiting enzyme in the nicotinamide adenine dinucleotide salvage pathway. Mechanistically, the NAMPT gene is located at 7q22.3, and deletion of 1 copy due to -7/-7q results in NAMPT haploinsufficiency, leading to reduced expression and a therapeutically targetable vulnerability to the inhibition of NAMPT. Our results show that in -7/-7q AML, differentiated CD34+CD38+ myeloblasts are more sensitive to the inhibition of NAMPT than less differentiated CD34+CD38- myeloblasts. Furthermore, the combination of the BCL2 inhibitor venetoclax and the NAMPT inhibitor KPT-9274 resulted in the death of significantly more leukemic blasts in AML samples with -7/-7q than the NAMPT inhibitor alone. In conclusion, our findings demonstrate that AML with -7/-7q is highly sensitive to NAMPT inhibition, suggesting that NAMPT inhibitors have the potential to be an effective targeted therapy for patients with monosomy 7 or del(7q)., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2024
Full Text
View/download PDF

37. Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022.

Author

Meslé MMI, Sinnathamby M, Mook P, Pebody R, Lakhani A, Zambon M, Popovici O, Lazăr M, Ljubović AD, Vukmir NR, Altaş AB, Avci E, Łuniewska K, Szymański K, Gargasiene G, Muralyte S, Dziugyte A, Zahra G, Gonçalves AR, Spedaliero T, Fournier G, Alvarez-Vaca D, Petrović G, Tabain I, Prosenc K, Socan M, Protic J, Dimitrijevic D, Druc A, Apostol M, Kalasnikova KK, Nikisins S, Reiche J, Cai W, Meijer A, Teirlinck A, Larrauri A, Casas I, Enouf V, Vaux S, Lomholt FK, Trebbien R, Jirincova H, Sebestova H, Rózsa M, Molnár Z, Aspelund G, Baldvinsdottir GE, Cottrell S, Moore C, Kossyvakis A, Mellou K, Sadikova O, Tamm JK, Bossuyt N, Thomas I, Staroňová E, Kudasheva L, Pleshkov B, Ikonen N, Helve O, Dickson E, Curran T, Komissarova K, Stolyarov K, Vysotskaya V, Shmialiova N, Rakočević B, Vujošević D, Abovyan R, Sargsyan S, Zakhashvili K, Machablishvili A, Koshalko O, Demchyshyna I, Mandelboim M, Glatman-Freedman A, Gunson R, Karanwal S, Guiomar R, Rodrigues AP, Bennett C, Domegan L, Kalaveshi A, Jakupi X, Ovliyakulova G, Korsun N, and Vladimirova N

Subjects
Humans, Seasons, Pandemics, Population Surveillance, SARS-CoV-2, COVID-19 epidemiology, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections epidemiology
Abstract

Background: The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in early 2020 and subsequent implementation of public health and social measures (PHSM) disrupted the epidemiology of respiratory viruses. This work describes the epidemiology of respiratory syncytial virus (RSV) observed during two winter seasons (weeks 40-20) and inter-seasonal periods (weeks 21-39) during the pandemic between October 2020 and September 2022., Methods: Using data submitted to The European Surveillance System (TESSy) by countries or territories in the World Health Organization (WHO) European Region between weeks 40/2020 and 39/2022, we aggregated country-specific weekly RSV counts of sentinel, non-sentinel and Severe Acute Respiratory Infection (SARI) surveillance specimens and calculated percentage positivity. Results for both 2020/21 and 2021/22 seasons and inter-seasons were compared with pre-pandemic 2016/17 to 2019/20 seasons and inter-seasons., Results: Although more specimens were tested than in pre-COVID-19 pandemic seasons, very few RSV detections were reported during the 2020/21 season in all surveillance systems. During the 2021 inter-season, a gradual increase in detections was observed in all systems. In 2021/22, all systems saw early peaks of RSV infection, and during the 2022 inter-seasonal period, patterns of detections were closer to those seen before the COVID-19 pandemic., Conclusion: RSV surveillance continued throughout the COVID-19 pandemic, with an initial reduction in transmission, followed by very high and out-of-season RSV circulation (summer 2021) and then an early start of the 2021/22 season. As of the 2022/23 season, RSV circulation had not yet normalised., Competing Interests: The following authors declare having received funding from the Innovative Medicines Initiative (IMI): Adam Meijer (The Netherlands) and Anne Teirlinck (The Netherlands). All other authors have no conflicts of interest to declare., (© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

38. Highly pathogenic avian influenza A(H5N1) virus infection in foxes with PB2-M535I identified as a novel mammalian adaptation, Northern Ireland, July 2023.

Author

Lagan P, McKenna R, Baleed S, Hanna B, Barley J, McConnell S, Georgaki A, Sironen T, Kauppinen A, Gadd T, Lindh E, Ikonen N, McMenamy MJ, and Lemon K

Subjects
Animals, Foxes, Northern Ireland epidemiology, Phylogeny, Influenza in Birds, Influenza A Virus, H5N1 Subtype genetics, Influenza A virus genetics
Abstract

We report cases of mammalian infection with highly pathogenic avian influenza (HPAI) virus A(H5N1) clade 2.3.4.4b in Northern Ireland. Two common gulls ( Larus canus ) and two red fox kits ( Vulpes vulpes ), were found dead in close vicinity. Comparison of viral whole genome sequences obtained from the animals identified a novel mammalian adaptation, PB2-M535I. Analysis of genetic sequences from other recent mammalian infections shows that this mutation has arisen on at least five occasions in three European countries since April 2023.

Published
2023
Full Text
View/download PDF

39. Highly pathogenic avian influenza A(H5N1) virus infection on multiple fur farms in the South and Central Ostrobothnia regions of Finland, July 2023.

Author

Lindh E, Lounela H, Ikonen N, Kantala T, Savolainen-Kopra C, Kauppinen A, Österlund P, Kareinen L, Katz A, Nokireki T, Jalava J, London L, Pitkäpaasi M, Vuolle J, Punto-Luoma AL, Kaarto R, Voutilainen L, Holopainen R, Kalin-Mänttäri L, Laaksonen T, Kiviranta H, Pennanen A, Helve O, Laamanen I, Melin M, Tammiranta N, Rimhanen-Finne R, Gadd T, and Salminen M

Subjects
Animals, Farms, Finland epidemiology, Mink, Phylogeny, Influenza A virus, Influenza A Virus, H5N1 Subtype genetics, Influenza in Birds epidemiology
Abstract

Since mid-July 2023, an outbreak caused by highly pathogenic avian influenza A(H5N1) virus clade 2.3.4.4b genotype BB is ongoing among farmed animals in South and Central Ostrobothnia, Finland. Infections in foxes, American minks and raccoon dogs have been confirmed on 20 farms. Genetic analysis suggests introductions from wild birds scavenging for food in farm areas. Investigations point to direct transmission between animals. While no human infections have been detected, control measures are being implemented to limit spread and human exposure.

Published
2023
Full Text
View/download PDF

40. High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021.

Author

Dub T, Solastie A, Hagberg L, Liedes O, Nohynek H, Haveri A, Virta C, Vara S, Lasander M, Ekström N, Österlund P, Lind K, Valtonen H, Hemmilä H, Ikonen N, Lukkarinen T, Palmu AA, and Melin M

Abstract

Background: Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time., Methods: In Spring 2020, we invited confirmed COVID-19 cases and their household members to four visits, where we collected nasopharyngeal and serum samples over 28 days after index case onset. We calculated SAR based on the presence of SARS-CoV-2 neutralizing antibodies (NAb) and assessed the persistence of NAb and IgG antibodies (Ab) against SARS-CoV-2 spike glycoprotein and nucleoprotein., Results: SAR was 45% (39/87), including 35 symptomatic secondary cases. During the initial 28-day follow-up, 62% (80/129) of participants developed NAb. Of those that seroconverted, 90% (63/70), 85% (63/74), and 78% (45/58) still had NAb to early B-lineage SARS-CoV-2 3, 6, and 12 months after the onset of the index case. Anti-spike IgG Ab persisted in 100% (69/69), 97% (72/74), and 93% (55/59) of seroconverted participants after 3, 6, and 12 months, while anti-nucleoprotein IgG Ab levels waned faster, persisting in 99% (68/69), 78% (58/74), and 55% (39/71) of participants, respectively., Conclusion: Following detection of a COVID-19 case in a household, other members had a high risk of becoming infected. NAb to early B-lineage SARS-CoV-2 persisted for at least a year in most cases., Competing Interests: The Finnish Institute for Health and Welfare had received research funding for studies not related to COVID-19 from GlaxoSmithKline Vaccines (NE, CV, AP, and MM as investigators), Pfizer (AP), and Sanofi Pasteur (AP). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Dub, Solastie, Hagberg, Liedes, Nohynek, Haveri, Virta, Vara, Lasander, Ekström, Österlund, Lind, Valtonen, Hemmilä, Ikonen, Lukkarinen, Palmu and Melin.)

Published
2022
Full Text
View/download PDF

41. Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021.

Author

Vauhkonen H, Nguyen PT, Kant R, Plyusnin I, Erdin M, Kurkela S, Liimatainen H, Ikonen N, Blomqvist S, Liitsola K, Lindh E, Helve O, Jarva H, Loginov R, Palva A, Hannunen T, Hannula S, Parry M, Kauppi P, Vaheri A, Sironen T, Lappalainen M, Savolainen-Kopra C, Smura T, and Vapalahti O

Subjects
Finland epidemiology, Humans, COVID-19 epidemiology, SARS-CoV-2 genetics
Abstract

Multiple introductions of SARS-COV-2 Omicron variant BA.1 and BA.1.1. lineages to Finland were detected in early December 2021. Within 3 weeks, Omicron overtook Delta as the most common variant in the capital region. Sequence analysis demonstrated the emergence and spread through community transmission of a large cluster of BA.1.1 virus.

Published
2022
Full Text
View/download PDF

42. Genomic and epidemiological report of the recombinant XJ lineage SARS-CoV-2 variant, detected in northern Finland, January 2022.

Author

Lindh E, Smura T, Blomqvist S, Liitsola K, Vauhkonen H, Savolainen L, Ikonen J, Ronkainen J, Taskila J, Taskila T, Sakaranaho P, Savolainen-Kopra C, Vapalahti O, and Ikonen N

Subjects
Finland epidemiology, Genomics, Humans, COVID-19 epidemiology, SARS-CoV-2 genetics
Abstract

Recombinant sequences of the SARS-CoV-2 Omicron variant were detected in surveillance samples collected in north-western Finland in January 2022. We detected 191 samples with an identical genome arrangement in weeks 3 to 11, indicating sustained community transmission. The recombinant lineage has a 5'-end of BA.1, a recombination breakpoint between orf1a and orf1b (nucleotide position 13,296-15,240) and a 3'-end of BA.2 including the S gene. We describe the available genomic and epidemiological data about this currently circulating recombinant XJ lineage.

Published
2022
Full Text
View/download PDF

43. Incidence Trends for SARS-CoV-2 Alpha and Beta Variants, Finland, Spring 2021.

Author

Kant R, Nguyen PT, Blomqvist S, Erdin M, Alburkat H, Suvanto M, Zakham F, Salminen V, Olander V, Paloniemi M, Huhti L, Lehtinen S, Luukinen B, Jarva H, Kallio-Kokko H, Kurkela S, Lappalainen M, Liimatainen H, Hannula S, Halkilahti J, Ikonen J, Ikonen N, Helve O, Gunell M, Vuorinen T, Plyusnin I, Lindh E, Ellonen P, Sironen T, Savolainen-Kopra C, Smura T, and Vapalahti O

Subjects
Finland epidemiology, Humans, Incidence, Phylogeny, COVID-19, SARS-CoV-2
Abstract

Severe acute respiratory syndrome coronavirus 2 Alpha and Beta variants became dominant in Finland in spring 2021 but had diminished by summer. We used phylogenetic clustering to identify sources of spreading. We found that outbreaks were mostly seeded by a few introductions, highlighting the importance of surveillance and prevention policies.

Published
2021
Full Text
View/download PDF

44. Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021.

Author

Benschop KS, Albert J, Anton A, Andrés C, Aranzamendi M, Armannsdóttir B, Bailly JL, Baldanti F, Baldvinsdóttir GE, Beard S, Berginc N, Böttcher S, Blomqvist S, Bubba L, Calvo C, Cabrerizo M, Cavallero A, Celma C, Ceriotti F, Costa I, Cottrell S, Del Cuerpo M, Dean J, Dembinski JL, Diedrich S, Diez-Domingo J, Dorenberg D, Duizer E, Dyrdak R, Fanti D, Farkas A, Feeney S, Flipse J, De Gascun C, Galli C, Georgieva I, Gifford L, Guiomar R, Hönemann M, Ikonen N, Jeannoël M, Josset L, Keeren K, López-Labrador FX, Maier M, McKenna J, Meijer A, Mengual-Chuliá B, Midgley SE, Mirand A, Montes M, Moore C, Morley U, Murk JL, Nikolaeva-Glomb L, Numanovic S, Oggioni M, Palminha P, Pariani E, Pellegrinelli L, Piralla A, Pietsch C, Piñeiro L, Rabella N, Rainetova P, Uceda Renteria SC, Romero MP, Reynders M, Roorda L, Savolainen-Kopra C, Schuffenecker I, Soynova A, Swanink CM, Ursic T, Verweij JJ, Vila J, Vuorinen T, Simmonds P, Fischer TK, and Harvala H

Subjects
Communicable Disease Control, Disease Outbreaks, Europe epidemiology, Humans, SARS-CoV-2, COVID-19, Enterovirus, Enterovirus D, Human genetics, Enterovirus Infections diagnosis, Enterovirus Infections epidemiology, Myelitis epidemiology, Respiratory Tract Infections
Abstract

We report a rapid increase in enterovirus D68 (EV-D68) infections, with 139 cases reported from eight European countries between 31 July and 14 October 2021. This upsurge is in line with the seasonality of EV-D68 and was presumably stimulated by the widespread reopening after COVID-19 lockdown. Most cases were identified in September, but more are to be expected in the coming months. Reinforcement of clinical awareness, diagnostic capacities and surveillance of EV-D68 is urgently needed in Europe.

Published
2021
Full Text
View/download PDF

45. Clinical validation of automated and rapid mariPOC SARS-CoV-2 antigen test.

Author

Koskinen JM, Antikainen P, Hotakainen K, Haveri A, Ikonen N, Savolainen-Kopra C, Sundström K, and Koskinen JO

Subjects
Adult, Aged, Antigens, Viral analysis, COVID-19 immunology, Cross Reactions immunology, Female, Finland epidemiology, Humans, Immunoassay methods, Male, Middle Aged, Nasopharynx virology, RNA, Viral genetics, Reproducibility of Results, SARS-CoV-2 immunology, SARS-CoV-2 pathogenicity, Sensitivity and Specificity, COVID-19 diagnosis, COVID-19 Serological Testing methods
Abstract

COVID-19 diagnostics was quickly ramped up worldwide early 2020 based on the detection of viral RNA. However, based on the scientific knowledge for pre-existing coronaviruses, it was expected that the SARS-CoV-2 RNA will be detected from symptomatic and at significant rates also from asymptomatic individuals due to persistence of non-infectious RNA. To increase the efficacy of diagnostics, surveillance, screening and pandemic control, rapid methods, such as antigen tests, are needed for decentralized testing and to assess infectiousness. A novel automated mariPOC SARS-CoV-2 test was developed for the detection of conserved structural viral nucleocapsid proteins. The test utilizes sophisticated optical laser technology for two-photon excitation and individual detection of immunoassay solid-phase particles. We validated the new method against qRT-PCR. Sensitivity of the test was 100.0% (13/13) directly from nasopharyngeal swab specimens and 84.4% (38/45) from swab specimens in undefined transport mediums. Specificity of the test was 100.0% (201/201). The test's limit of detection was 2.7 TCID 50 /test. It showed no cross-reactions. Our study shows that the new test can detect infectious individuals already in 20 min with clinical sensitivity close to qRT-PCR. The mariPOC is a versatile platform for syndromic testing and for high capacity infection control screening of infectious individuals., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

46. Detection of SARS-CoV-2 Infection in Gargle, Spit, and Sputum Specimens.

Author

Poukka E, Mäkelä H, Hagberg L, Vo T, Nohynek H, Ikonen N, Liitsola K, Helve O, Savolainen-Kopra C, and Dub T

Subjects
Adult, Diagnostic Tests, Routine, Female, Humans, Male, Middle Aged, Nasopharynx, Respiratory System virology, Saliva, COVID-19 diagnosis, COVID-19 Testing methods, SARS-CoV-2 isolation & purification, Specimen Handling methods, Sputum virology
Abstract

The gold standard for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis is reverse transcription (RT)-PCR from a nasopharyngeal swab specimen (NPS). Its collection involves close contact between patients and health care workers, requiring a significant amount of workforce and putting them at risk of infection. We evaluated self-collection of alternative specimens and compared their sensitivity and cycle threshold ( C T ) values to those of NPS. We visited acute coronavirus disease 2019 (COVID-19) outpatients to collect concomitant NPS and gargle specimens and had patients self-collect gargle and either sputum or spit specimens the next morning. We included 40 patients and collected 40 concomitant NPS and gargle specimens, as well as 40 gargle, 22 spit, and 16 sputum specimens the next day (2 patients could not produce sputum). All specimens were as sensitive as NPS. Gargle specimens had a sensitivity of 0.97 (95% confidence interval [CI], 0.92 to 1.00), whether collected concomitantly with NPS or the next morning. Next-morning spit and sputum specimens showed sensitivities of 1.00 (95% CI, 1.00 to 1.00) and 0.94 (95% CI, 0.87 to 1.00]), respectively. The gargle specimens had significantly higher mean C T values of 29.89 (standard deviation [SD], 4.63; P < 0.001) and 29.25 (SD, 3.99; P < 0.001) when collected concomitantly and the next morning, respectively, compared to NPS (22.07 [SD, 4.63]). C T values obtained with spit (23.51 [SD, 4.57]; P = 0.11) and sputum (25.82 [SD, 9.21]; P = 0.28) specimens were close to those of NPS. All alternative specimen collection methods were as sensitive as NPS, but spit collection appeared more promising, with a low C T value and ease of collection. Our findings warrant further investigation. IMPORTANCE Control of the COVID-19 pandemic relies heavily on a test-trace-isolate strategy. The most commonly used specimen for diagnosis of SARS-CoV-2 infection is a nasopharyngeal swab. However, this method is quite uncomfortable for the patient, requires specific equipment (nose swabs and containers), and requires close proximity to health care workers, putting them at risk of infection. Developing alternative sampling strategies could decrease the burden for health care workers, help overcome potential shortages of equipment, and improve acceptability of testing by reducing patient discomfort.

Published
2021
Full Text
View/download PDF

47. An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021.

Author

Hetemäki I, Kääriäinen S, Alho P, Mikkola J, Savolainen-Kopra C, Ikonen N, Nohynek H, and Lyytikäinen O

Subjects
COVID-19 Vaccines, Disease Outbreaks, Finland epidemiology, Health Personnel, Hospitals, Humans, Secondary Care, COVID-19, SARS-CoV-2
Abstract

An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) spread from one inpatient in a secondary care hospital to three primary care facilities, resulting in 58 infections including 18 deaths in patients and 45 infections in healthcare workers (HCW). Only one of the deceased cases was fully vaccinated. Transmission occurred despite the use of personal protective equipment by the HCW, as advised in national guidelines, and a high two-dose COVID-19 vaccination coverage among permanent staff members in the COVID-19 cohort ward.

Published
2021
Full Text
View/download PDF

48. Epidemiology of laboratory-confirmed influenza among kidney transplant recipients compared to the general population-A nationwide cohort study.

Author

Helanterä I, Gissler M, Rimhanen-Finne R, Ikonen N, Kanerva M, Lempinen M, and Finne P

Subjects
Cohort Studies, Humans, Incidence, Laboratories, Risk Factors, Transplant Recipients, Influenza, Human diagnosis, Influenza, Human epidemiology, Kidney Transplantation adverse effects
Abstract

Seasonal influenza causes morbidity and mortality after organ transplantation. We quantified the detection of laboratory-confirmed influenza among kidney transplant recipients compared to the general population in a nationwide cohort. All laboratory-confirmed cases of influenza and hospitalizations due to influenza among all kidney transplant recipients in our country between 1995 and 2017 were captured with database linkage from statutory national registries. Data from the general population of Finland, population 5.5 million, were used for comparisons. Annual incidences of influenza and hospitalizations due to influenza, and standardized incidence ratios (SIR) were calculated. Altogether 3904 kidney transplant recipients with a total follow-up of 37 175 patient-years were included. Incidence of laboratory-confirmed influenza was 9.0 per 1000 patient years in 2003-2019, and 18.0 per 1000 patient years during 2015-2019. The risk of laboratory-confirmed influenza was significantly higher among kidney transplant recipients compared to the general population (SIR 5.1, 95% CI 4.5-5.7). SIR for hospitalization due to influenza was 4.4 (95% CI 3.4-4.7). Mortality of the hospitalized patients was 9%, and 5% of the patients with laboratory-confirmed influenza. Detection of laboratory-confirmed influenza is increased fivefold and risk of hospitalization due to influenza more than fourfold among kidney transplant recipients compared to the general population., (© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.)

Published
2021
Full Text
View/download PDF

49. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.

Author

Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, Gonzalez G, Garcia-Leon A, Crispie F, O'Connor L, Murphy N, Mossong J, Vergison A, Wienecke-Baldacchino AK, Abdelrahman T, Riccardo F, Stefanelli P, Di Martino A, Bella A, Lo Presti A, Casaca P, Moreno J, Borges V, Isidro J, Ferreira R, Gomes JP, Dotsenko L, Suija H, Epstein J, Sadikova O, Sepp H, Ikonen N, Savolainen-Kopra C, Blomqvist S, Möttönen T, Helve O, Gomes-Dias J, and Adlhoch C

Subjects
Critical Care, Europe epidemiology, Humans, COVID-19, SARS-CoV-2
Abstract

We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8).

Published
2021
Full Text
View/download PDF

50. Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients - a prospective observational study.

Author

Auvinen R, Nohynek H, Syrjänen R, Ollgren J, Kerttula T, Mäntylä J, Ikonen N, Loginov R, Haveri A, Kurkela S, and Skogberg K

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, COVID-19 diagnosis, COVID-19 mortality, COVID-19 virology, Cardiovascular Diseases diagnosis, Cardiovascular Diseases mortality, Cardiovascular Diseases virology, Comorbidity, Diabetes Mellitus diagnosis, Diabetes Mellitus mortality, Diabetes Mellitus virology, Female, Finland epidemiology, Hospitalization, Humans, Incidence, Influenza, Human diagnosis, Influenza, Human mortality, Influenza, Human virology, Intensive Care Units, Male, Middle Aged, Prospective Studies, Reverse Transcriptase Polymerase Chain Reaction, Severity of Illness Index, Survival Analysis, Tertiary Care Centers, Tomography, X-Ray Computed, COVID-19 epidemiology, Cardiovascular Diseases epidemiology, Diabetes Mellitus epidemiology, Influenza, Human epidemiology, Orthomyxoviridae pathogenicity, SARS-CoV-2 pathogenicity
Abstract

Background: We compared the clinical characteristics, findings, and outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) or influenza to detect relevant differences., Methods: From December 2019 to April 2020, we recruited all eligible hospitalized adults with respiratory infection to a prospective observational study at a tertiary care hospital in Finland. Influenza and SARS-CoV-2 infections were confirmed by RT-PCR. Follow-up lasted for 3 months from admission., Results: We included 61 patients, of whom 28 were COVID-19 and 33 influenza patients with median ages of 53 and 56 years. Majority of both COVID-19 and influenza patients were men (61% vs. 67%) and had at least one comorbidity (68% vs. 85%). Pulmonary diseases and current smoking were less common among COVID-19 than influenza patients (5 [18%] vs. 15 [45%], p =.03 and 1 [4%] vs. 10 [30%], p =.008). In chest X-ray at admission, ground-glass opacities (GGOs) and consolidations were more frequent among COVID-19 than influenza patients (19 [68%] and 7 [21%], p <.001). Severe disease and intensive care unit (ICU) admission occurred more often among COVID-19 than influenza patients (26 [93%] vs. 19 [58%], p =.003 and 8 [29%] vs. 2 [6%], p =.034). COVID-19 patients were hospitalized longer than influenza patients (six days [IQR 4-21] vs. 3 [2-4], p <.001)., Conclusions: Bilateral GGOs and consolidations in chest X-ray may help to differentiate COVID-19 from influenza. Hospitalized COVID-19 patients had more severe disease, required longer hospitalization and were admitted to ICU more often than influenza patients, which has important implications for public health policies.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results